Jon Gruber on AI and Healthcare
MIT economist Jon Gruber discusses how economic analysis can help us think about the real costs of new technology in healthcare systems—and why the hardest questions aren't technical, but about tradeoffs.
In this conversation, Gruber explains how healthcare markets differ from typical markets, why insurance creates unique incentive problems, and how AI might help or hurt depending on how we deploy it. He also reflects on what it means to teach economics in a way that helps students think clearly about hard problems.
Transcript
Host: Welcome to Chalk Radio, a podcast about inspired teaching at MIT. I'm your host, and today we're talking with Jon Gruber, the Ford Professor of Economics at MIT, about how economic thinking can help us understand the promises and pitfalls of AI in healthcare.
Jon, thanks for being here.
Jon Gruber: Thanks for having me. This is a topic I've been thinking about a lot lately, especially as we see more and more AI tools entering clinical practice.
Host: So let's start with the basics. When economists think about healthcare, what makes it different from other markets?
Jon Gruber: Healthcare is unique because of what we call information asymmetry. When you buy a car, you can kick the tires, read reviews, compare prices. But when you're sick, you often don't know what's wrong, what treatment you need, or whether your doctor is any good. That creates all sorts of problems.
Host: And how does AI fit into that picture?
Jon Gruber: That's the interesting question. On one hand, AI could reduce information asymmetry by giving patients better diagnostic tools and more transparent treatment recommendations. On the other hand, it could make things worse if the AI systems are opaque black boxes that nobody understands, or if they're optimized for the wrong objectives.
Host: What do you mean by the wrong objectives?
Jon Gruber: Well, imagine an AI trained to minimize hospital readmissions. Sounds good, right? But it might do that by recommending longer initial stays or more aggressive treatments that aren't actually better for patients. The incentives matter enormously.